Joan Mancuso

Great infographic from the inaugural #ESCardioOnco2025 conference highlighting atherosclerosis associated w/#CheckpointInhibitors #oncsky #oncologynursing @pallonccop.bsky.social
@escardio.bsky.social

Excited to head out this week to share the #BestofASCO in #pallonc and #supponc later this week. Join us!

@fumikochino.bsky.social
@tingtingzhang.bsky.social
@ericroeland.bsky.social
@darcyburbage.bsky.social
@oncoalert.bsky.social
@weoncologists.bsky.social
@pallonccop.bsky.social

Congratulations to @maryamlustberg.bsky.social named an inaugural @cancercaremascc.bsky.social Fellow during #mascc25!

Development of a Multi-Institutional Dataset to Validate a Novel Inflammatory Breast Cancer Diagnostic Score AbstractPurpose. Susan G. Komen, the Inflammatory Breast Cancer (IBC) Research Foundation, and the Milburn Foundation convened patient advocates, clinician

Thrilled to share work from our @mdanderson.bsky.social IBC team & the IBC team at @dfcibreastonc.bsky.social led by Dr. Filipa Lynce Komen and @ibcresearch1.bsky.social support to validate a new IBC scoring system to improve IBC diagnosis! #medsky #ibcsky #cansky academic.oup.com/jnci/advance...

Excited to share our latest pre-print “Soluble E-cadherin Drives Brain Metastasis in Inflammatory Breast Cancer” led by the outstanding Xiaoding Hu, an instructor in my lab. #Breastcancer #Brainmetastasis #IBC #Ecadherin #ReactiveAstrocytes #CXCR2

👉 biorxiv.org/content/10.110…

SCOTUS upheld that health plans must continue to cover preventive services, including cancer screenings, w/o patient cost-sharing. We’re proud to have joined 33 other patient & med groups advocating for this essential coverage brnw.ch/21wTKb7

Our manuscript highlighting the design, goals, and experiences of the MBCRC Advocate Researcher Program (MARP), which focused on building meaningful, bidirectional partnerships between advocates and researchers was published in npj breast. www.nature.com/articles/s41...

The MBCRC Advocate Researcher Program (MARP): connecting advocates and researchers as collaborative partners in cancer research - npj Breast Cancer npj Breast Cancer - The MBCRC Advocate Researcher Program (MARP): connecting advocates and researchers as collaborative partners in cancer research

It is an honor to collaborate with excellent advocates, clinicians and scientists on an ongoing project to develop long-term, bi-directional relationships with early career researchers, and what we learned.

www.nature.com/articles/s41...

@drnataliagandur.bsky.social
@kjankovic.bsky.social
@elisaagostinetto.bsky.social
@joanmancusombc.bsky.social
@ascocancer.bsky.social
@crisbergerot.bsky.social
@tingtingzhang.bsky.social
@fionnualacrowley.bsky.social
@ericroeland.bsky.social
@mazietsangmd.bsky.social
@darcyburbage.bsky.social

Many times as a #MedOnc I qualify my #PallOnc colleagues. In this case, our #PallOnc NP qualified me! So grateful for
@parkviewhealth.bsky.social for choosing her story to tell. #pancsm #GIonc

@oncoalert.bsky.social
@weoncologists.bsky.social
@pallonccop.bsky.social
@biagioricciutimd.bsky.social

Kudos and gratitude to the organizers, attendees, and fellow faculty members for today's Workshop 1: Partnering with patients in managing chronic toxicities of cancer and its treatment #MASCC25
@maryamlustberg.bsky.social @tingtingzhang.bsky.social @ericroeland.bsky.social @brueraeduardo.bsky.social

A path to precision metabolic treatment in breast cancer: riluzole, glutamate signaling, and invasiv... Matthew J Sikora, Julie H Ostrander; A path to precision metabolic treatment in breast cancer: riluzole, glutamate signaling, and invasive lobular carcinoma, Jo

@jostrander.bsky.social and I had the opportunity to write a commentary on @profriggins.bsky.social latest work in JES - @zmadake2.bsky.social - looking toward really cool implications for understanding and leveraging the unique metabolism of lobular breast cancer.

academic.oup.com/jes/advance-...

Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers NR2F2 modulates the ER cistrome, coregulator interactions, and chromatin accessibility to promote endocrine resistance in ER+ breast cancer.

Link from CRISPR news:
Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers | Science Translational Medicine www.science.org/doi/10.1126/...

Midkine inhibits dormancy of disseminated melanoma cells A significant factor in cancer-related mortality in melanoma is the appearance of intrinsically aggressive distal metastases. This recurrence frequently results from the awakening of dormant dissemina...

Important findings from the @soledadsosalab.bsky.social at the @cdi-einstein.bsky.social at Montefiore Einstein Comprehensive Cancer Center on the mechanisms of dormant cutaneous melanoma awakening via midkine dependent signaling. Congrats on this story!
www.biorxiv.org/content/10.1...

"The rich debates over race-specific hemoglobin thresholds reveal physicians’ changing conceptions of racial equity." Medicine and Society "Debating Race and the Diagnosis of Anemia — How Medicine Moved Away from Race-Based Standards" by Wingel Xue, B.S., and David S. Jones, M.D., Ph.D.

As physicians continue to debate the role of race in clinical algorithms, the unusual history of debates over race-specific anemia diagnosis may be instructive, write the authors of a new Medicine and Society article. Learn more: nej.md/4kTAt8I

#MedSky #Hematology #HealthPolicy

Guess who’s co-presenting w/ an OSW at #AOSW2025 next week? ME!!! Bridging the OSW expertise & cancer patient perspective in our session. We’ll explore strategies to build trust with patients, recognize and address biases, and drive more equitable, compassionate care. #advocate

Great moment with the lab celebrating Lucía Petriz Otaño🇦🇷 passing her PhD qualifying exam and receiving her MSc!! Congratulations! We are very proud of you! @cdi-einstein.bsky.social @einsteincellbio.bsky.social

It's been my greatest joy to be a part of this community in my #earlycareer. Thanksful to have had the priveldge of leading with Dr @mazietsangmd.bsky.social and looking forward to this year with Dr @crisbergerot.bsky.social #pallonc #supponc
@tingtingzhang.bsky.social
@ericroeland.bsky.social

Genetic testing can be life-changing, but only if patients can access it. At #ASCO25, we spoke with MD Anderson’s Julie Moskowitz about her work to simplify and expand germline testing for young-onset colorectal cancer. #EndCancer @gcjuliemosk.bsky.social

‘Devasting.’ NIH cancels future funding plans for HIV vaccine consortia Researchers decry agency’s decision just as new leads reinvigorate search for long-sought vaccine

Headline says it all.

www.science.org/content/arti...

Foundation models and intelligent decision-making: Progress, challenges, and perspectives Intelligent Decision-Making (IDM) is a cornerstone of artificial intelligence (AI), designed to automate or augment decision processes. Modern IDM par…

Foundation models and intelligent decision-making: Progress, challenges, and perspectives.

www.sciencedirect.com/science/arti...

#TIC2025 #ArtificialInteligence #Science #AI #TechnologyNews

@darcyburbage.bsky.social
@crisbergerot.bsky.social
@tingtingzhang.bsky.social
@fionnualacrowley.bsky.social
@oncoalert.bsky.social
@weoncologists.bsky.social
@elisabettabonzano.bsky.social
@kjankovic.bsky.social
@elisaagostinetto.bsky.social
@joanmancusombc.bsky.social

@mazietsangmd.bsky.social
@fionnualacrowley.bsky.social
@tingtingzhang.bsky.social
@fumikochino.bsky.social
@maryamlustberg.bsky.social
@joanmancusombc.bsky.social
@coffeemommy.bsky.social
@jillfeldman4.bsky.social

We are very excited for our in person meeting on Monday at #ASCO25. If you’re interested in whole person care for patients with cancer please join us!

@ascocancer.bsky.social
@crisbergerot.bsky.social
@ericroeland.bsky.social
@realbowtiedoc.bsky.social
@darcyburbage.bsky.social

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer... Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-03 study of Trodelvy® (sacituzumab govitecan-hziy). The...

www.businesswire.com/news/home/20...

Cost and Cost-Effectiveness of Treating Human Epidermal Growth Factor Receptor 2–Low Metastatic Breast Cancer PURPOSECreating value-aligned treatment pathways in breast cancer requires understanding the cost and cost-effectiveness of new therapies. To address uncertainty in the optimal treatment sequence, we ...

ascopubs.org/doi/10.1200/...

Routine Surveillance for Cancer Metastases — Does It Help or Harm Patients? | NEJM Research generally suggests that routine surveillance after cancer treatment finds more recurrences — leading to more surgery, chemotherapy, and radiation — without affecting the risk of death.

Routine Surveillance for Cancer Metastases — Does It Help or Harm Patients? | New England Journal of Medicine www.nejm.org/doi/full/10....

Mark Cuban Does It Again: Reshuffling the Deck of Front-Line CML Therapy With the currently available BCR::ABL1 tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has transformed from an invariably fatal disorder (10-year overall survival < 10%) to an indolent o...

ascopost.com/news/may-202...

Strategy for Managing Immunotherapy-Induced Parkinsonism in Patients With Multiple Myeloma The JAK (Janus kinase) inhibitor ruxolitinib may prove to be an effective treatment of parkinsonism arising from immunotherapy for patients with multiple myeloma, according to the results of two case ...

ascopost.com/issues/may-2...

@elisaagostinetto.bsky.social
@joanmancusombc.bsky.social
@ascocancer.bsky.social
@crisbergerot.bsky.social
@tingtingzhang.bsky.social
@fionnualacrowley.bsky.social
@ericroeland.bsky.social
@mazietsangmd.bsky.social
@darcyburbage.bsky.social
@ryannipp.bsky.social
@pallonccop.bsky.social